Published in J Inflamm (Lond) on July 27, 2010
Dendritic cells and aging: consequences for autoimmunity. Expert Rev Clin Immunol (2012) 0.86
Longevity of SLE-prone mice increased by dietary 2-mercaptoethanol via a mechanism imprinted within the first 28 days of life. Virulence (2010) 0.83
The Mycobacterium avium subsp. paratuberculosis fibronectin attachment protein, a toll-like receptor 4 agonist, enhances dendritic cell-based cancer vaccine potency. Exp Mol Med (2012) 0.83
Resveratrol prevents dendritic cell maturation in response to advanced glycation end products. Oxid Med Cell Longev (2013) 0.82
Regulation of Dendritic Cell Function in Inflammation. J Immunol Res (2015) 0.79
Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. J Control Release (2015) 0.79
Engineering lentiviral vectors for modulation of dendritic cell apoptotic pathways. Virol J (2013) 0.78
Leukotriene C(4) prevents the complete maturation of murine dendritic cells and modifies interleukin-12/interleukin-23 balance. Immunology (2011) 0.78
Type I Interferon Counters or Promotes Coxiella burnetii Replication Dependent on Tissue. Infect Immun (2016) 0.76
Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. Mediators Inflamm (2016) 0.75
The Importance of Dendritic Cells in Maintaining Immune Tolerance. J Immunol (2017) 0.75
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. Oncotarget (2017) 0.75
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
Taking dendritic cells into medicine. Nature (2007) 11.82
The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol (2003) 8.28
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol (2006) 6.62
Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol (2000) 5.13
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis (2006) 4.29
Dendritic cells in intestinal immune regulation. Nat Rev Immunol (2008) 4.20
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis (2006) 3.29
alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 3.00
Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol (2006) 2.92
Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol (2004) 2.38
The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum (2005) 2.07
Pathogen subversion of cell-intrinsic innate immunity. Nat Immunol (2007) 1.97
Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 1.96
Type 17 T helper cells-origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol (2009) 1.90
Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J (2008) 1.78
Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol (2007) 1.76
IL-23: a master regulator in Crohn disease. Nat Med (2007) 1.59
The IL23 axis plays a key role in the pathogenesis of IBD. Gut (2007) 1.58
The cytokine and chemokine network in psoriasis. Clin Dermatol (2007) 1.31
Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol (2008) 1.27
Chemokines: more than just road signs. Nat Rev Immunol (2006) 1.24
Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol (2005) 1.23
Monocyte-derived dendritic cells exposed to Der p 1 allergen enhance the recruitment of Th2 cells: major involvement of the chemokines TARC/CCL17 and MDC/CCL22. Eur Cytokine Netw (2004) 0.97
Chemokines orchestrate leukocyte trafficking in inflammatory bowel disease. Front Biosci (2008) 0.95
CD4 T cell-induced, bid-dependent apoptosis of cutaneous dendritic cells regulates T cell expansion and immune responses. J Immunol (2006) 0.83
Induction of regulatory dendritic cells by dexamethasone and 1alpha,25-Dihydroxyvitamin D(3). Immunol Lett (2004) 0.98
Dexamethasone/1alpha-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model. Immunology (2008) 0.90
CXC chemokine receptor 3 expression increases the disease-inducing potential of CD4+ CD25- T cells in adoptive transfer colitis. Inflamm Bowel Dis (2006) 0.86
Colitic scid mice fed Lactobacillus spp. show an ameliorated gut histopathology and an altered cytokine profile by local T cells. Inflamm Bowel Dis (2005) 0.86
Genome-wide expression profiling during protection from colitis by regulatory T cells. Inflamm Bowel Dis (2008) 0.82
Development of assay platforms for in vitro screening of Treg modulating potential of pharmacological compounds. Immunopharmacol Immunotoxicol (2014) 0.76
Chemokines involved in protection from colitis by CD4+CD25+ regulatory T cells. Inflamm Bowel Dis (2006) 0.76
Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist. Expert Opin Drug Deliv (2015) 0.75